GlobalData Plc
  • Press Release

    Majority of pharma professionals now say Brexit will have a negative impact on the UK healthcare sector

Negative sentiment amongst healthcare professionals about the impact of Brexit on the UK healthcare sector has increased over the last 3 months, according to GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘Brexit and the Healthcare Industry – Implications for Pharma, Q3 2018’, reveals that 59% of healthcare industry professionals now have a negative sentiment about Brexit’s impact on the UK healthcare sector, compared to only 42% who expressed the same opinion in June 2018. Healthcare professionals from the US, UK and EU took part in the survey with respondents from the EU expressing the biggest fall in Brexit confidence, with a 28% increase in negative sentiment since the previous survey.

IMAGE FOR PUBLICATION: Please click link for chart: Healthcare Industry Survey

The report is based on a quarterly survey of participants from the pharmaceutical industry, both within and outside the UK, who were asked about the impact of Brexit on the healthcare sector as well as their evolving sentiment towards Brexit.

Alexandra Annis, MS, Managing Healthcare Analyst at GlobalData, commented, “One potential explanation for the increase in negative sentiment in Q3 is less clarity over the future of Brexit, especially in the EU. The Brexit process has a long way to go and is filled with uncertainty as a ‘no deal’ Brexit becomes an increasing possibility.’’

The UK pharmaceutical industry is one of the country’s largest and most dynamic sectors, and a major contributor to the economy. As well as being the home to pharmaceutical giants GlaxoSmithKline and AstraZeneca, many other leading international pharmaceutical companies have sizeable operations in the UK.

Annis continues, ‘‘Given the importance of the pharmaceutical industry to the UK economy, the current negativity around Brexit must be of concern. Understanding the impact of Brexit on research and manufacturing, corporate strategy, and relocation as well as tracking the evolving sentiment of Brexit’s impact on the UK healthcare industry is of significant importance to help pharmaceutical companies make the most of Britain leaving the EU.”

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF